Cargando…
Preclinical characterization and anti-SARS-CoV-2 efficacy of ATV014: an oral cyclohexanecarboxylate prodrug of 1′-CN-4-aza-7,9-dideazaadenosine C-nucleoside
| Autores principales: | , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group UK
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9835026/ https://www.ncbi.nlm.nih.gov/pubmed/36635259 http://dx.doi.org/10.1038/s41392-023-01310-0 |
| _version_ | 1784868588175228928 |
|---|---|
| author | Zhou, Qifan Yang, Sidi Cao, Liu Yang, Yang Xu, Tiefeng Chen, Qishu Lu, Hongzhou Li, Yingjun Guo, Deyin Zhang, Xumu |
| author_facet | Zhou, Qifan Yang, Sidi Cao, Liu Yang, Yang Xu, Tiefeng Chen, Qishu Lu, Hongzhou Li, Yingjun Guo, Deyin Zhang, Xumu |
| author_sort | Zhou, Qifan |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9835026 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | Nature Publishing Group UK |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-98350262023-01-14 Preclinical characterization and anti-SARS-CoV-2 efficacy of ATV014: an oral cyclohexanecarboxylate prodrug of 1′-CN-4-aza-7,9-dideazaadenosine C-nucleoside Zhou, Qifan Yang, Sidi Cao, Liu Yang, Yang Xu, Tiefeng Chen, Qishu Lu, Hongzhou Li, Yingjun Guo, Deyin Zhang, Xumu Signal Transduct Target Ther Letter Nature Publishing Group UK 2023-01-12 /pmc/articles/PMC9835026/ /pubmed/36635259 http://dx.doi.org/10.1038/s41392-023-01310-0 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
| spellingShingle | Letter Zhou, Qifan Yang, Sidi Cao, Liu Yang, Yang Xu, Tiefeng Chen, Qishu Lu, Hongzhou Li, Yingjun Guo, Deyin Zhang, Xumu Preclinical characterization and anti-SARS-CoV-2 efficacy of ATV014: an oral cyclohexanecarboxylate prodrug of 1′-CN-4-aza-7,9-dideazaadenosine C-nucleoside |
| title | Preclinical characterization and anti-SARS-CoV-2 efficacy of ATV014: an oral cyclohexanecarboxylate prodrug of 1′-CN-4-aza-7,9-dideazaadenosine C-nucleoside |
| title_full | Preclinical characterization and anti-SARS-CoV-2 efficacy of ATV014: an oral cyclohexanecarboxylate prodrug of 1′-CN-4-aza-7,9-dideazaadenosine C-nucleoside |
| title_fullStr | Preclinical characterization and anti-SARS-CoV-2 efficacy of ATV014: an oral cyclohexanecarboxylate prodrug of 1′-CN-4-aza-7,9-dideazaadenosine C-nucleoside |
| title_full_unstemmed | Preclinical characterization and anti-SARS-CoV-2 efficacy of ATV014: an oral cyclohexanecarboxylate prodrug of 1′-CN-4-aza-7,9-dideazaadenosine C-nucleoside |
| title_short | Preclinical characterization and anti-SARS-CoV-2 efficacy of ATV014: an oral cyclohexanecarboxylate prodrug of 1′-CN-4-aza-7,9-dideazaadenosine C-nucleoside |
| title_sort | preclinical characterization and anti-sars-cov-2 efficacy of atv014: an oral cyclohexanecarboxylate prodrug of 1′-cn-4-aza-7,9-dideazaadenosine c-nucleoside |
| topic | Letter |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9835026/ https://www.ncbi.nlm.nih.gov/pubmed/36635259 http://dx.doi.org/10.1038/s41392-023-01310-0 |
| work_keys_str_mv | AT zhouqifan preclinicalcharacterizationandantisarscov2efficacyofatv014anoralcyclohexanecarboxylateprodrugof1cn4aza79dideazaadenosinecnucleoside AT yangsidi preclinicalcharacterizationandantisarscov2efficacyofatv014anoralcyclohexanecarboxylateprodrugof1cn4aza79dideazaadenosinecnucleoside AT caoliu preclinicalcharacterizationandantisarscov2efficacyofatv014anoralcyclohexanecarboxylateprodrugof1cn4aza79dideazaadenosinecnucleoside AT yangyang preclinicalcharacterizationandantisarscov2efficacyofatv014anoralcyclohexanecarboxylateprodrugof1cn4aza79dideazaadenosinecnucleoside AT xutiefeng preclinicalcharacterizationandantisarscov2efficacyofatv014anoralcyclohexanecarboxylateprodrugof1cn4aza79dideazaadenosinecnucleoside AT chenqishu preclinicalcharacterizationandantisarscov2efficacyofatv014anoralcyclohexanecarboxylateprodrugof1cn4aza79dideazaadenosinecnucleoside AT luhongzhou preclinicalcharacterizationandantisarscov2efficacyofatv014anoralcyclohexanecarboxylateprodrugof1cn4aza79dideazaadenosinecnucleoside AT liyingjun preclinicalcharacterizationandantisarscov2efficacyofatv014anoralcyclohexanecarboxylateprodrugof1cn4aza79dideazaadenosinecnucleoside AT guodeyin preclinicalcharacterizationandantisarscov2efficacyofatv014anoralcyclohexanecarboxylateprodrugof1cn4aza79dideazaadenosinecnucleoside AT zhangxumu preclinicalcharacterizationandantisarscov2efficacyofatv014anoralcyclohexanecarboxylateprodrugof1cn4aza79dideazaadenosinecnucleoside |